Evoke Pharma Inc (EVOK)
0.4788
-0.07
(-12.79%)
USD |
NASDAQ |
Apr 18, 16:00
0.5037
+0.02
(+5.20%)
After-Hours: 20:00
Evoke Pharma Research and Development Expense (Quarterly): 0.0226M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 0.0226M |
| September 30, 2023 | 0.00 |
| June 30, 2023 | 0.0924M |
| March 31, 2023 | 0.067M |
| December 31, 2022 | 0.0272M |
| September 30, 2022 | 0.0404M |
| June 30, 2022 | 0.1915M |
| March 31, 2022 | 0.0417M |
| December 31, 2021 | 0.0357M |
| September 30, 2021 | 0.0817M |
| June 30, 2021 | 0.1952M |
| March 31, 2021 | 0.2778M |
| December 31, 2020 | 0.1038M |
| September 30, 2020 | 0.205M |
| June 30, 2020 | 5.782M |
| March 31, 2020 | 0.4639M |
| December 31, 2019 | 0.6415M |
| September 30, 2019 | 0.8224M |
| June 30, 2019 | 1.206M |
| March 31, 2019 | 0.7469M |
| December 31, 2018 | 0.6954M |
| September 30, 2018 | 0.6255M |
| June 30, 2018 | 1.389M |
| March 31, 2018 | 1.385M |
| Date | Value |
|---|---|
| December 31, 2017 | 1.632M |
| September 30, 2017 | 2.718M |
| June 30, 2017 | 2.018M |
| March 31, 2017 | 0.7707M |
| December 31, 2016 | 1.502M |
| September 30, 2016 | 1.339M |
| June 30, 2016 | 2.095M |
| March 31, 2016 | 2.015M |
| December 31, 2015 | 1.708M |
| September 30, 2015 | 1.838M |
| June 30, 2015 | 2.188M |
| March 31, 2015 | 2.42M |
| December 31, 2014 | 2.176M |
| September 30, 2014 | 3.088M |
| June 30, 2014 | 2.875M |
| March 31, 2014 | 1.852M |
| December 31, 2013 | 0.6364M |
| September 30, 2013 | 0.0787M |
| June 30, 2013 | 0.1308M |
| March 31, 2013 | 0.111M |
| December 31, 2012 | 0.3183M |
| September 30, 2012 | 0.337M |
| June 30, 2012 | 0.213M |
| March 31, 2012 | 0.2973M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
Sep 2023
5.782M
Maximum
Jun 2020
0.542M
Average
0.1038M
Median
Dec 2020
Research and Development Expense (Quarterly) Benchmarks
| Eton Pharmaceuticals Inc | 1.047M |
| NovaBay Pharmaceuticals Inc | 0.004M |
| Palatin Technologies Inc | 5.554M |
| iBio Inc | 1.535M |
| Theriva Biologics Inc | 4.196M |